Results 221 to 230 of about 119,169 (307)

Impact of Early‐Line Systemic Therapies on Liver Function in Hepatocellular Carcinoma: Longitudinal Change of ALBI Score and Ammonia Level With and Without Anti‐VEGF Agents

Hepatology Research, EarlyView.
ABSTRACT Background and Aim Anti–vascular endothelial growth factor (VEGF) agents are widely used for hepatocellular carcinoma (HCC); inhibition of VEGF‐mediated liver regeneration may compromise hepatic reserve. We investigated the impact of anti‐VEGF therapy on liver function and risk factors for deterioration of albumin–bilirubin (ALBI) score during
Naoshi Nishida, Kazuomi Ueshima, Tomoko Aoki, Takuya Matsubara, Naoya Omaru, Natsuki Okai, Masahiro Morita, Hirokazu Chishina, Masahiro Takita, Satoru Hagiwara, Yasunori Minami, Masatoshi Kudo   +11 more
wiley   +1 more source

DART/SWOG/NCI phase II anti-CTLA-4/PD-1 trial: clear cell carcinomas of ovary, endometrium, cervix. [PDF]

J Immunother Cancer
Chae YK, Othus M, Patel SP, Backes FJ, O'Malley DM, Cristea M, Naing A, Kurnit K, Eskander RN, T Goodrich S, Robinson WR, Scalici J, Chan J, Ali-Ahmad H, Hays J, McCormick C, Kim EJ, Sueblinvong T, Ahmed A, Siedel J, Thomes Pepin J, Bottsford-Miller JN, Fagbemi SO, Jaslowski AJ, Kim HS, Chung LI, Moloney-Lineen C, McLeod CM, Chen HX, Sharon E, Streicher H, Ryan CW, Blanke CD, Kurzrock R.   +33 more
europepmc   +1 more source

Atypical Melanosis on Acral Skin or Early Acral Lentiginous Melanoma? Reappraising an Ambiguous Concept in Acquired Acral Pigmented Lesions

Journal of Cutaneous Pathology, EarlyView.
Marcial Álvarez‐Salafranca, Pedro Gil‐Pallares, Alba Navarro‐Bielsa, Tamara Gracia‐Cazaña, Carlos Monteagudo, María Carmen Gómez‐Mateo   +5 more
wiley   +1 more source

Mucous Membrane Pemphigoid After Anti‐PD‐1 Therapy: Risk‐Stratified Management and Treatment Outcomes

International Journal of Dermatology, EarlyView.
ABSTRACT Mucous membrane pemphigoid (MMP) following anti‐programmed cell death‐1 (PD‐1) therapy is rare but increasingly reported. Management of high‐ and low‐risk MMP in this setting and the potential oncologic trade‐offs remain poorly defined. We performed a narrative synthesis of all published cases of anti‐PD‐1‐associated MMP, following MEDLINE ...
Serena Dienes, Negar Esfandiari, Steven Daveluy   +2 more
wiley   +1 more source

Neuroinflammation in CTLA-4 Haploinsufficiency: Case Report of a New Variant with Remarkable Response to Targeted Therapy. [PDF]

Int J Mol Sci
Baldini L, Del Vecchio L, Cerasi S, Fetta A, Moratti M, Bezzi A, Ferrari S, Di Dalmazi G, Rossi S, Toni F, Cordelli DM, Lanari M, Conti F.   +12 more
europepmc   +1 more source

Defining the tumor microenvironment of non‐small cell lung cancer

Immunology &Cell Biology, EarlyView.
The tumor microenvironment (TME) in non‐small cell lung cancer is highly heterogeneous, both at a patient level and tumor microenvironment resolution. Defining the tumor microenvironment from patient‐responders and non‐responders will aid in the development of targeted therapeutics specific for each individual patient.
Kidane Siele Embaye, Tony Blick, Vahid Yaghoubi Naei, Ken O'Byrne, Brett G. M. Hughes, Arutha Kulasinghe   +5 more
wiley   +1 more source

Immune checkpoint inhibitor cardiomyotoxicity: a case series of five patients and development of a clinical management algorithm

Internal Medicine Journal, EarlyView.
Abstract Immune checkpoint inhibitor (ICI) therapies have revolutionised the management of a range of malignancies. However, the syndrome of ICI induced cardiomyotoxicity, also reported as triple “M” syndrome (myasthenia gravis, myositis and myocarditis) is an unfortunate severe consequence in up to 1%–2% of patients receiving ICI, with an associated ...
S. Z. Xie, J. E. Salem, A. Nagrial, A. Menzies, L. Thomas, S. Ramanathan, L. J. Berglund, S. C. Sasson, A. C. Grey, R. Habib, M. Wong, M. S. Carlino, B. Jeffrey, J. Mo, M. W. Lin   +14 more
wiley   +1 more source

Peripheral Immune Remodeling After Spinal Cord Injury: Marked by Expansion of CD38⁺, CTLA-4⁺, and PD-1⁺ T and NK Cells. [PDF]

Neurol Neuroimmunol Neuroinflamm
Veeningen N, Añé-Kourí AL, Pues A, Rubio S, Fraussen J, Ioannou C, Martens DS, van Laake-Geelen CCM, Deckers J, Cornips EMJ, Bamps S, Gysemberg G, Van Broeckhoven J, Hellings N, Slaets H.   +14 more
europepmc   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source